Could the second half of the year be as much fun as the first?
News & Analysis: Arrowhead Pharmaceuticals
The biopharma company started several new clinical trials and enjoyed success in others since the start of the calendar year.
Here's how they could continue to climb.
The clinical-stage developer of RNAi therapies is being added to the S&P 600 index.
ARWR earnings call for the period ending March 31, 2019.
Investors cheered the news in a fiscal first-quarter 2019 earnings report.
The company announced fiscal first-quarter 2019 financial results and provided an update for the year ahead.
ARWR earnings call for the period ending December 31, 2018.
A reversal of fortunes made last year one for the record books.
The company updated investors on its financial performance, and on its progress developing RNAi therapies.